For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers
NCT07716748 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 66
Last updated 2026-07-21
Summary
This study is to evaluate differences in the gut and follicle/scalp microbiome signature in AGA compared to a non-AGA population. Also, to investigate differences in inflammation and other biomarkers in AGA compared to non-AGA population at baseline and after a successful treatment
Conditions
Sponsors & Collaborators
-
National Skin Centre
lead NETWORK
Eligibility
- Min Age
- 21 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-08-31
- Primary Completion
- 2028-01-31
- Completion
- 2028-01-31
More Related Trials
-
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
NCT07080931 ·Status: RECRUITING ·Phase: PHASE3
-
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
NCT05864885 ·Status: UNKNOWN ·Phase: PHASE1
-
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
NCT06146166 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Clinical Study to Evaluate the Safety, Effectiveness and In-Use Tolerability of Hair Growth and Scalp Health Serum in Subjects With Mild to Moderate Hair Thinning.
NCT07195487 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
NCT06747611 ·Status: RECRUITING ·Phase: PHASE2
-
Minoxidil Response Testing in Females With Female Pattern Hair Loss
NCT02206802 ·Status: COMPLETED
-
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
NCT07529977 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
NCT07370519 ·Status: RECRUITING ·Phase: PHASE2
-
Development and Standardization Methods
NCT06802237 ·Status: COMPLETED
-
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
NCT06924632 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
NCT07273799 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
NCT06590779 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
NCT03831334 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Phase III Study of KX-826 With Adult Male Patients With AGA
NCT06126965 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Trial in Females for Female Pattern Hair Loss
NCT01226459 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial in Females With Female Pattern Hair Loss
NCT01145625 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
NCT01501617 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata
NCT07459933 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
NCT07011485 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
NCT05636904 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT05417308 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Low Dose Oral Minoxdil in Androgenic Alopecia
NCT07018349 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia
NCT01319370 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
NCT03709563 ·Status: TERMINATED ·Phase: NA
-
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
NCT05324293 ·Status: COMPLETED ·Phase: PHASE1